← All trials
NCT00020566
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2001
- Primary completion
- Dec 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1200
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of LeicesterLead sponsor
- Societe Francaise Oncologie PediatriqueCollaborator
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - AustriaCollaborator
- St. Anna KinderkrebsforschungStudy chair
- University of MunsterStudy chair
- University of LeedsStudy chair
- University of WashingtonStudy chair
- Balgrist UniversitaetsStudy chair
- National Cancer Institute (NCI)Collaborator
- Children's Cancer and Leukaemia GroupCollaborator
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - GermanyCollaborator
- Swiss Group for Clinical Cancer ResearchCollaborator
- EBMT Solid Tumors Working PartyCollaborator
- European Organisation for Research and Treatment of CancerCollaborator
- Institut Gustave RoussyStudy chair
- University of LondonOfficial
- University of MelbourneStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.